✦ LIBER ✦

Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide

✍ Scribed by PAULSON, J

Book ID: 122824911
Publisher: Elsevier Science
Year: 1985
Tongue: English
Weight: 532 KB
Volume: 5
Category: Article
ISSN: 0272-0590
DOI: 10.1016/0272-0590(85)90058-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The chemopreventive agent N-(4-hydroxyph

The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family

✍ Boya, Patricia; Morales, Maria Celia; Gonzalez-Polo, Rosa-Ana; Andreau, Karine; 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 438 KB

Effect of N-(4-hydroxyphenyl)retinamide

Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells

✍ Thomas T.Y. Wang; James M. Phang 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 911 KB

ANTAGONISTIC EFFECTS OF SODIUM BUTYRATE

ANTAGONISTIC EFFECTS OF SODIUM BUTYRATE AND N-(4- HYDROXYPHENYL)RETINAMIDE ON PROSTATE CANCER

✍ R. Kuefer; F. Genze; W. Zugmaier; L. Rinnab; R.E. Hautmann; B. Buechele 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Therapeutic effect of N-(4-hydroxyphenyl

Therapeutic effect of N-(4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea-induced rat mammary cancer

✍ Dowlatshahi, K.; Mehta, R.G.; Thomas, C.F.; Dinger, N.M.; Moon, R.C. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 527 KB

Modulation of the malignant phenotype of

Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR)

✍ Mukta M. Webber; Diana Bello-DeOcampo; Salmaan Quader; Nestor D. Deocampo; W. Sc 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 159 KB

Cyclosporin A enhances the apoptotic eff

Cyclosporin A enhances the apoptotic effects of N-(4-hydroxyphenyl)retinamide in breast cancer cells

✍ Soo-Jeong Lim; Ann-Marie Simeone; Chong-Kook Kim; Ana M. Tari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 140 KB

4HPR, an analogue of ATRA, effectively induces growth inhibition and apoptosis in breast cancer cell lines and animal models but is ineffective against advanced human breast tumors. Different compounds, including tamoxifen, are currently being tested to increase 4HPR efficacy in the clinic. Here, we